A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC

SIMPLE SUMMARY: Pembrolizumab + chemotherapy and nivolumab + ipilimumab are approved first-line treatment options for patients with metastatic stage IV NSCLC with a PD-L1 tumor proportion score (TPS) ≥1%. Understanding the differences between these treatment options is required to inform clinical de...

Descripción completa

Detalles Bibliográficos
Autores principales: Halmos, Balazs, Burke, Thomas, Kalyvas, Chrysostomos, Insinga, Ralph, Vandormael, Kristel, Frederickson, Andrew, Piperdi, Bilal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762014/
https://www.ncbi.nlm.nih.gov/pubmed/33291810
http://dx.doi.org/10.3390/cancers12123648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762014/
https://www.ncbi.nlm.nih.gov/pubmed/33291810
http://dx.doi.org/10.3390/cancers12123648

Ejemplares similares